CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

08 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

06 сен 2022 07:00:02 Источник Nasdaq GlobeNewswire

New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism

02 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

12 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 авг 2022 15:44:12 Источник Nasdaq GlobeNewswire

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

04 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июл 2022 16:09:22 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 июн 2022 15:30:47 Источник Nasdaq GlobeNewswire

Crinetics Presents Clinical and Research Results at ENDO 2022

08 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

07 июн 2022 06:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

25 май 2022 06:00:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

12 май 2022 15:41:57 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 май 2022 15:18:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

18 апр 2022 15:01:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

12 апр 2022 22:52:43 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 апр 2022 16:15:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

30 мар 2022 15:02:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

30 мар 2022 15:01:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer

21 мар 2022 06:30:00 Источник Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 мар 2022 16:20:34 Источник Nasdaq GlobeNewswire